Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Postoperative S-1 monotherapy in pancreatic cancer
ChiCTR1800014607Phase 4Recruiting
- Sponsor
- Tongji Hospital, Huazhong University of Science and Technology
- Start
- Jan 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of tegafur in pancreatic cancer (PC) and pancreatic adenocarcinoma (PDAC), sponsored by Tongji Hospital, Huazhong University of Science and Technology. Primary endpoints: Overall survival and Disease-free survival. Started Jan 2016; status: recruiting.
02
Drugs
tegafur
03
Conditions
pancreatic cancer (PC)pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on ChiCTR1800014607.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR1800014607.